Business
Distribution Agreement for Quo-Test HbA1c Analyzer
Distribution Agreement for Quo-Test HbA1c Analyzer.
About this update from Ekf Diagnostics Holdings Plc
[{"type":"text","content":"\n \n \n RNS Number : 8947L\n EKF Diagnostics Holdings PLC\n 05 May 2020\n \n \n \n \n EKF Diagnostics Holdings plc\n (\"EKF\", the \"Company\" or the \"Group\")\n \n \n Distribution Agreement for\n Quo-Test HbA1c Analyzer\n \n \n EKF Diagnostics Holdings plc (AIM: EKF), the AIM quoted point-of-care business, announces that it has signed a three-year distribution agreement with Tosoh Europe N.V., part of Tosoh Corporation, the global chemical and specialty materials company, for the distribution of the Company's Quo-Test HbA1c Analyzer in the Middle East and Africa.\n \n \n EKF's Quo-Test is a fully automated desktop HbA1c (glycated hemoglobin) analyzer that provides easy and reliable HbA1c measurement for monitoring and managing diabetes in a Point-of-Care setting, such as diabetes clinics and doctors' surgeries. The sample results are available within four minutes from a 4 microliter sample taken from a finger prick or venous whole blood. Step by step instructions displayed on the Quo-Test analyzer's clear, multi-lingual display, reduce staff training time to a minimum, eliminating the opportunity for user-related errors.\n \n \n \n \n \n The Tosoh Bioscience division is one of the largest global manufacturers of High Performance Liquid Chromatography (HPLC) equipment for glycated hemoglobin analysis, offering scalable solutions predominantly in core laboratories. Tosoh Europe have seen a growing need for Point-of-Care HbA1c analysis alongside their traditional laboratory market and have identified EKF Diagnostics as an important partner to work with them to provide this to their customers. The agreement will allow both EKF and Tosoh Europe to work in markets they have previously been unable to access and provides Tosoh Europe with the opportunity to offer new services to suit changing customer requirements.\n \n \n After the initial three-year term for the Middle East and Africa, the agreement has a rolling one-year renewal with the option to extend the agreement into EU countries as required.\n \n \n Commenting, Julian Baines, CEO of EKF, said: \"\n We are delighted to partner with Tosoh Europe as they expand their need for Point-of-Care analysis in a time where those suffering from diabetes are at greater risk. This new agreement continues to strengthen the ...